Is Avatrombopag included in medical insurance?
Avatrombopag (Avatrombopag) The original drug is already on the market in China, with the generic name of Avatrombopag Maleate Tablets and sold under the trade name Su Kexin. It has passed the relevant regulations of the National Medical Insurance Administration and entered the scope of Class B medical insurance. However, it is only available for adult patients with chronic liver disease-related thrombocytopenia who are scheduled to undergo elective diagnostic procedures or surgeries for reimbursement through national medical insurance. Patients who do not meet the conditions can only purchase the drug at their own expense.

After being approved by the US Food and Drug Administration (FDA) overseas, avatrombopag is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who plan to undergo surgery, and is also indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an inadequate response to previous treatment. Avatrombopag is clinically an orally bioavailable small-molecule thrombopoietin (TPO) receptor agonist that stimulates the proliferation and differentiation of megakaryocytes in bone marrow progenitor cells, thereby increasing platelet production by not competing with thrombopoietin for binding to the TPO receptor and having an additive pharmacological effect with TPO on platelet production.
The original drug of avatrombopag marketed in China, with a common specification of 20mg*15 tablets, may cost more than 7,000 yuan per box, while the original drug of avatrombopag marketed overseas is even more expensive. It is understood that there are generic drugs of avatrombopag available overseas, and their pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of a box of 20mg*30 tablets in Laos pharmaceutical production specifications may be around RMB 1,000 (the price may fluctuate due to exchange rates). For specific price and drug information of avatrombopag, please consult a medical consultant.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)